Real-world clinical outcomes among US Veterans with oral factor xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate

Oral factor Xa (FXa) inhibitors significantly reduce incidence of stroke and thromboembolic events in patients with atrial fibrillation or venous thromboembolism. Due to various factors and the lack of a randomized controlled trial comparing andexanet alfa to usual care, non-specific replacement age...

Descripción completa

Detalles Bibliográficos
Autores principales: Sutton, S. Scott, Magagnoli, Joseph, Cummings, Tammy H., Dettling, Theresa, Lovelace, Belinda, Christoph, Mary J., Hardin, James W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284962/
https://www.ncbi.nlm.nih.gov/pubmed/37219827
http://dx.doi.org/10.1007/s11239-023-02820-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284962/
https://www.ncbi.nlm.nih.gov/pubmed/37219827
http://dx.doi.org/10.1007/s11239-023-02820-y

Ejemplares similares